锆-89标记PSMA PET/CT延迟显像用于PSA≤0.2 ng/mL前列腺癌生化复发早期检测的可行性研究
本研究纳入65例生化复发且PSA≤0.2 ng/mL的前列腺癌患者,行[89Zr]Zr-PSMA PET/CT延迟显像(平均注射活度129.0±19.3 MBq,摄取时间48 h)。总体阳性率达72.3%,Gleason评分≥8者阳性率更高(p=0.047),提示该显像在极低PSA水平下具有较高敏感性。
要点
- PSA≤0.2 ng/mL的生化复发患者中,[89Zr]Zr-PSMA PET/CT总体阳性率为72.3%。
- Gleason评分≥8的患者阳性率显著高于低评分者(p=0.047)。
- 局部复发25例,淋巴结转移29例,骨转移4例。
核心结论
- 在PSA≤0.2 ng/mL的生化复发患者中,[89Zr]Zr-PSMA PET/CT单中心65例队列阳性率达72.3%。
- 该显像在极低PSA浓度下具有显著敏感性,可能有助于早期识别复发并指导个体化靶向治疗。
研究设计与样本
- 单中心可行性研究,分析65例生化复发且PSA≤0.2 ng/mL的前列腺癌患者。
- 显像时平均PSA为0.14±0.04 ng/mL,平均注射活度129.0±19.3 MBq,摄取时间48 h。
- 评估阳性率及扫描阳性的潜在预测因素,包括PSA水平、PSA倍增时间和初始Gleason评分。
主要发现
- 总体阳性率为72.3%,65例中47例至少存在一个可疑病灶。
- 局部复发25例,淋巴结转移29例,骨转移4例。
- Gleason评分≥8的患者阳性率高于低评分者(p=0.047)。
临床怎么用
- 对于PSA≤0.2 ng/mL的生化复发患者,可考虑使用[89Zr]Zr-PSMA PET/CT延迟显像以提高复发灶检出。
- Gleason评分≥8的患者可能从该显像中获益更明显。
局限性
- 本研究为单中心可行性研究,样本量65例,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: PSMA PET/CT using PSMA ligands labeled with the long-lived radionuclide zirconium-89 represents a promising novel imaging approach for prostate cancer. Preliminary evidence indicates that [89Zr]Zr-PSMA PET/CT may enhance the detection of tumor lesions in patients with biochemical recurrence (BCR). This study aims to evaluate the positivity rate and feasibility of [89Zr]Zr-PSMA imaging in patients with very low PSA levels (≤ 0.2 ng/mL). METHODS: Sixty-five patients with BCR and PSA levels ≤ 0.2 ng/mL undergoing [89Zr]Zr-PSMA PET/CT were analyzed. The mean PSA level at imaging was 0.14 ± 0.04 ng/mL. PET/CT was performed using a mean injected activity of 129.0 ± 19.3 MBq and an uptake time of 48 h. Positivity rates and potential predictors of scan positivity, including PSA level, PSA doubling time, and initial Gleason score, were evaluated. RESULTS: [89Zr]Zr-PSMA PET/CT achieved a high overall positivity rate of 72.3%, with 47 of 65 patients presenting with at least one suspicious lesion. Local recurrence was detected in 25 patients, while lymph node and bone metastases were observed in 29 and 4 patients, respectively. Patients with a Gleason score ≥ 8 exhibited a higher positivity rate than those with lower scores (p = 0.047). CONCLUSION: In patients with BCR and PSA levels ≤ 0.2 ng/mL, [89Zr]Zr-PSMA PET/CT yielded a 72.3% positivity rate in this single-center cohort of 65 individuals. This notable sensitivity at minimal PSA concentrations may enable early identification of recurrent disease and facilitate individualized targeted therapy.
引用
- Speicher T, Latell S, Blickle A, et al. Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study. Eur J Nucl Med Mol Imaging. 2026. PMID: 41940956. doi:10.1007/s00259-026-07854-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。